SCHEMBL15023642

SCHEMBL15023642

CCOCc1cc2c(N)ncnn2c1C=O

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 20/20 0.35
▸ FGFR3 P22607 9/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15019260 0.87 LMNA (0.34) FGFR1FGFR3
SCHEMBL15023612 0.80 TNIK (0.33) —
SCHEMBL15023105 0.72 FGFR1 (0.39) FGFR1FGFR3
SCHEMBL15023895 0.68 FGFR1 (0.44) FGFR1FGFR3
SCHEMBL22132829 0.67 LMNA (0.37) FGFR1FGFR3
SCHEMBL15023696 0.66 KIT (0.41) FGFR1FGFR3
SCHEMBL15020062 0.63 ACVRL1 (0.39) FGFR1FGFR3
SCHEMBL15047968 0.61 KIT (0.31) —
SCHEMBL15023008 0.61 KIT (0.31) —
SCHEMBL15020389 0.61 FGFR1 (0.36) FGFR1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153745-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2022-05-19 — — US disclosed
US-20190016724-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2019-01-17 — — US disclosed
US-20190016724-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2019-01-17 — — US disclosed
CN-104245700-B Dibasic benzothienyl-pyrrolo-triazine and the purposes as FGFR inhibitors of kinases thereof 拜耳制药股份公司 2016-11-16 — — CN disclosed
EP-2791140-B1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS Bayer Pharma AG (DE) 2016-06-15 — — EP disclosed
EP-2791140-B1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS Bayer Pharma AG (DE) 2016-06-15 — — EP disclosed
US-9206184-B2 Disubstituted benzothienyl-pyrrolotriazines and uses thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-08 — — US disclosed
US-9206184-B2 Disubstituted benzothienyl-pyrrolotriazines and uses thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-08 — — US disclosed
US-9206184-B2 Disubstituted benzothienyl-pyrrolotriazines and uses thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-08 — — US disclosed
CN-104245700-A Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors Bayer Pharma AG 2014-12-24 — — CN disclosed
US-20140336173-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-11-13 — — US disclosed
US-20140336173-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-11-13 — — US disclosed
US-20140336173-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-11-13 — — US disclosed
WO-2013087578-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2013-06-20 — — WO disclosed
US-20130158000-A1 Disubstituted benzothienyl-pyrrolotriazines and uses thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-20 — — US disclosed
US-20130158000-A1 Disubstituted benzothienyl-pyrrolotriazines and uses thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-20 — — US disclosed
US-20130158000-A1 Disubstituted benzothienyl-pyrrolotriazines and uses thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153745-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS NR5A2, FGFR1, FGFR3 FGFR1 2/4885FGFR3 3/4885
US-20130158000-A1 Disubstituted benzothienyl-pyrrolotriazines and uses thereof STK25, CDK5, JAK2 FGFR1 216/4885FGFR3 580/4885
US-20140336173-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS NR5A2, NR2C2, FGFR1 FGFR1 3/4885FGFR3 4/4885
US-20190016724-A1 DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS FGFR1, NR5A2, FGFR3 FGFR1 1/4885FGFR3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback